Post-Traumatic Stress Disorder - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2018, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 127 pages “Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Post-Traumatic Stress Disorder (PTSD) - Overview, Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development, Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment, Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development, Post-Traumatic Stress Disorder (PTSD) - Drug Profiles, Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, Appendix. This report Covered Companies - Addex Therapeutics Ltd, Amorsa Therapeutics Inc, Aptinyx Inc, Azevan Pharmaceuticals Inc, Bionomics Ltd, Catalyst Pharmaceuticals Inc, Chronos Therapeutics Ltd, Corcept Therapeutics Inc, Eli Lilly and Co, Embera NeuroTherapeutics Inc, Immodulon Therapeutics Ltd, Johnson & Johnson, Marinus Pharmaceuticals Inc, NeuroNascent Inc, Omeros Corp, Otsuka Holdings Co Ltd, Pragma Therapeutics SAS, SpringWorks Therapeutics LLC, Synchroneuron Inc, Tonix Pharmaceuticals Holding Corp.

Please visit this link for more details: http://mrr.cm/UPC

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UMh

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UPy